Graham Capital Management’s 4D Molecular Therapeutics FDMT Stock Holding History

Graham Capital Management’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$160K	Buy	+12,003	New	+$117K	﹤0.01%	1082
2025 Q2	–	Sell	-43,080	Closed	-$139K	–	1386
2025 Q1	$139K	Buy	+43,080	New	+$203K	﹤0.01%	1176
2024 Q4	–	Sell	-19,773	Closed	-$214K	–	1310
2024 Q3	$214K	Buy	19,773 +5,124	+35%	+$85K	﹤0.01%	889
2024 Q2	$307K	Buy	+14,649	New	+$367K	0.01%	724

Other funds holding FDMT

Jupiter Topco New York $245B AUM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Graham Capital Management's FDMT Position: Q2 2026 in Review

Graham Capital Management opened a new position in 4D Molecular Therapeutics (FDMT) in Q2 2026: 12,003 shares worth $160K. The stake represents ﹤0.01% of the portfolio and ranks #1082 among its holdings. This is a return to the name: Graham Capital Management previously reported a position in FDMT as recently as Q1 2025.

Graham Capital Management first reported a position in FDMT in Q2 2024 and has held it in 4 quarters since. The position peaked at $307K in Q2 2024. 157 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

Graham Capital Management held 12,003 shares of 4D Molecular Therapeutics worth $160K as of Q2 2026.
4D Molecular Therapeutics was a new Graham Capital Management position in Q2 2026.
4D Molecular Therapeutics made up ﹤0.01% of Graham Capital Management's portfolio in Q2 2026, its #1082 holding.
Graham Capital Management first reported a position in 4D Molecular Therapeutics in Q2 2024 and has held it in 4 quarters since.
Graham Capital Management's 4D Molecular Therapeutics position peaked at $307K in Q2 2024.
157 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Graham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.